Cargando…

P1109: TRIAL IN PROGRESS: PHASE 1B/2 TRIAL OF TAZEMETOSTAT IN COMBINATION WITH VARIOUS TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

Detalles Bibliográficos
Autores principales:	Bessudo, A., Greenwald, D., Kazemi, M. H., Mahindra, A., Shunyakov, L., Sondhi, M., O’Connor, H., Chen, Y., Yang, J., Salles, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429483/ http://dx.doi.org/10.1097/01.HS9.0000847304.04017.68

Ejemplares similares

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat
por: Raychaudhuri, Ruben, et al.
Publicado: (2022)

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes
por: Proudman, David G., et al.
Publicado: (2022)

Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
por: Izutsu, Koji, et al.
Publicado: (2021)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2021)

Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
por: Bekric, Dino, et al.
Publicado: (2023)

1109. Valgancyclovir Dosing for Cytomegalovirus Prophylaxis in Heart Transplant Recipients
por: Huang, Glen, et al.
Publicado: (2020)

Pharmacokinetics of Herb-Drug Interactions of Plumbagin and Tazemetostat in Rats by UPLC-MS/MS
por: Li, Heng, et al.
Publicado: (2022)

Endosomal trafficking defects in patient cells with KIAA1109 biallelic variants
por: Kane, Megan S., et al.
Publicado: (2019)

ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTAT
por: Nakata, Satoshi, et al.
Publicado: (2020)

KIAA1109 Variants Are Associated with a Severe Disorder of Brain Development and Arthrogryposis
por: Gueneau, Lucie, et al.
Publicado: (2018)

1109 Knowledge and Attitudes of Pregnant Women Towards Recommendations for Immunization During Pregnancy
por: Healy, C. Mary, et al.
Publicado: (2014)

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Joffe, E., et al.
Publicado: (2022)

A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
por: Proudman, David, et al.
Publicado: (2022)

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
por: Dawson, Mark A., et al.
Publicado: (2023)

A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
por: Williams, Brent A., et al.
Publicado: (2017)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

Cellular immunotherapy for refractory hematological malignancies
por: Reagan, John L, et al.
Publicado: (2013)

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
por: Alkharabsheh, Omar, et al.
Publicado: (2023)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

KIAA1109 gene mutation in surviving patients with Alkuraya-Kučinskas syndrome: a review of literature
por: Kumar, Kishore, et al.
Publicado: (2020)

1109P The psychological impact of COVID-19 pandemic on patients with NETs: Between resilience and vulnerability
por: Lauricella, E., et al.
Publicado: (2021)

1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
por: Kois, Abigail K, et al.
Publicado: (2021)

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial
por: Balasubramanian, Sriram, et al.
Publicado: (2021)

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
por: Jain, Salvia, et al.
Publicado: (2011)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment
por: Yuan, Hepei, et al.
Publicado: (2021)

Correction to: Aspinall S, et al. Human Vaccines and Immunotherapeutics Volume 8, Issue 8; pp.1109–18
por: Aspinall, Sanet, et al.
Publicado: (2013)

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
por: Nicolosi, Maura, et al.
Publicado: (2018)

SG-APSIC1109: Redesign of outpatient clinic clean care to decrease postoperative SSIs after orthopedic implants
por: Dahesihdewi, Andaru, et al.
Publicado: (2023)

P1109: EPIDEMIOLOGY OF CUTANEOUS T-CELL LYMPHOMAS: DATA ANALYSIS FROM THE MARCHE MULTIDISCIPLINARY TEAM (MDT) REGISTER.
por: Morsia, Erika, et al.
Publicado: (2023)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Characterizing the performance of two optical particle counters (Grimm OPC1.108 and OPC1.109) under urban aerosol conditions
por: Burkart, J., et al.
Publicado: (2010)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer
por: Lordick, F, et al.
Publicado: (2003)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h02vnb66ljbgi9fdj2ghhfk90b